Bioxyne Limited

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:12:24 2024-04-23 pm EDT			5-day change	1st Jan Change
0.007 ^AUD	-12.50%		-22.22%	-36.36%

Apr. 18	Bioxyne to Raise AU$1.45 Million via Share Issuance	MT
Feb. 29	Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Bioxyne Ltd : Expiry of Unquoted Options

December 04, 2013 at 03:25 am EST

MarketScreener.com By The editorial team

C-/Traverse Accountants Pty Ltd Suite 404, Level 4, 25 Lime Street Sydney NSW 2000

W: www.bioxyne.com
Australian Securities Exchange Companies Announcements Office SYDNEY 4 December 2013

Dear Sir/Madam

RE: OPTIONS EXPIRED

The Company wishes to advise that none of the following unquoted options were exercised by their expiry date:

Latest news about Bioxyne Limited

Bioxyne to Raise AU$1.45 Million via Share Issuance	Apr. 17	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%	Feb. 04	MT
Bioxyne Limited Announces Retirement of N H Chua as Director	Nov. 17	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11%	23-08-15	MT
Bioxyne Limited Extends Amazon Footprint into US and Japan	23-07-16	CI
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings	23-06-13	MT
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8%	23-06-12	MT
Bioxyne Limited Appoints Jason Hine as Director	23-05-22	CI
Bioxyne Acquires Breathe Life Sciences	23-05-22	MT
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd.	23-05-18	CI
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%	23-03-19	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Bioxyne's Fiscal H1 Revenue Declines	23-01-27	MT
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4%	22-12-18	MT
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.	22-12-18	CI
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer	22-12-18	CI
Bioxyne Sells 49% Stake in Direct Selling Business	22-10-24	MT
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million.	22-10-23	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Bioxyne Limited Announces Board Changes	22-06-07	CI
Bioxyne Posts Higher Sales Revenue in First Nine-Months of FY22	22-04-27	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-21	CI
Bioxyne's Revenue Surges 12% in Half-Year Ended Dec. 31, 2021	22-01-31	MT

Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOXYNE LIMITED	-36.36%	9.3M
IQVIA HOLDINGS INC.	+1.98%	43.84B
MODERNA, INC.	+6.59%	41.68B
LONZA GROUP AG	+45.09%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.73%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.27%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.28%	12.29B
MEDPACE HOLDINGS, INC.	+26.94%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.57%	11.15B